Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pediatric Protein-Losing Enteropathy Workup

  • Author: Simon S Rabinowitz, MD, PhD, FAAP; Chief Editor: Carmen Cuffari, MD  more...
 
Updated: Nov 17, 2015
 

Laboratory Studies

Patients with edema and documented hypoalbuminemia but without clinical or biochemical evidence of liver or renal disease should have a thorough evaluation for protein-losing enteropathy. In the past, protein-losing enteropathy was often considered a diagnosis of exclusion; however, several approaches for determining abnormal protein loss in the GI tract are currently noted. The ideal test for protein-losing enteropathy is able to detect a serum protein in the stool that is not secreted, digested, or reabsorbed in the GI tract. However, no ideal test is available.

Three established types of tests have been used to evaluate for protein-losing enteropathy. The earliest tests involved the intravenous administration of a radiolabeled substrate followed by the determination of radioactivity in the feces. The second type of test directly measures endogenous proteins in the feces. A third approach is the use of nuclear scintigraphy, not only for diagnosis, but also to identify potential regional or localized areas of protein loss. A recent publication described the use of MRI as an alternative method to diagnose and localize this condition.[27]

  • Radiolabeled Proteins
    • Use of radiolabeled proteins to measure albumin turnover dates back to 1950 with Kinsell.[28]  
    • In the late 1950s, Swartz, and later Citrin, administered iodine 131–albumin to patients in an attempt to measure albumin turnover. In a patient with hypertrophic gastritis and protein-losing enteropathy, Citrin reported that the131 I-albumin lost in the stomach was degraded and the free131 I was then absorbed and excreted in the urine, making the measurement of131 I in the stools unreliable.
    • In 1957, Gordon reported the use of polyvinylpyrrolidone iodine I 125 (131 I-PVP) as a marker for protein metabolism.[29]  PVP is a macromolecule that is not digested by intestinal enzymes and is poorly absorbed when taken by mouth. In patients with protein-losing enteropathy, intravenously administered131 I-PVP results in detectable levels of radioactivity in the stool. The problem with this substance is that it is not a normal metabolite, has a wide range of molecular weights, and can be partially absorbed and secreted. More importantly, the131 I is easily released from the carrier, which then can be absorbed and excreted in the urine. This is problematic if urine contamination of the stool occurs as in pediatric patients.
    • In 1961, the next radioactive substrate used was chromium 51–albumin. This method had several advantages. The51 Cr bound tightly to albumin and was poorly absorbed from the GI tract. Thus, little or no radioactivity was detectable in the urine.
    • In practice, approaches using radiolabeled compounds are now rarely used because 48-72 hours of stool collection is required in the hospital, care must be taken to avoid contamination of stool collection with urine, and the tests involve radiation exposure.
  • Endogenous Proteins
    • In 1977, Crossley and Elliot demonstrated that the stools of patients with protein-losing enteropathy as determined by51 Cr-albumin excretion also had high levels of alpha-1-antitrypsin, (A1-AT).
    • A1-AT is an endogenous protein not present in the diet; the molecular weight is similar to albumin. It is normally not actively secreted, absorbed, or digested.
    • A1-AT is stable in feces at 37°C, allowing collection over several days.
    • Because A1-AT is not excreted in urine, urine contamination of the stool sample does not alter the spot determination of fecal A1-AT.
    • Stool samples are simply lyophilized, and A1-AT is extracted by solubilization.
    • Fecal A1-AT can then be detected by immunoassay. Measurement of fecal A1-AT can be used as a spot determination or the clearance of A1-AT can be more formally calculated using the following formula:A1-AT clearance = [(fecal A1-AT concentration) (stool volume/24 h]/(A1-AT serum concentration)
    • Many studies have demonstrated the efficacy of using fecal A1-AT levels and A1-AT clearance for diagnosis and follow-up care in patients with protein-losing enteropathy.
Next

Imaging Studies

Nuclear scintigraphy

Several radiopharmaceuticals tagged to proteins have been used to examine protein-losing enteropathy, including indium-111 (In-111)–transferrin, technetium-99m (Tc-99m)–human serum albumin, and 99mTc-dextran. The latter compound is reported to be superior for numerous technical reasons.

Technetium Tc-99m MDP scintigraphy, an initial method of choice to detect skeletal metastases in cancer patients, was also reported to detect protein-losing enteropathy incidentally in a patient suspected of having bone metastases.[30]

Both Tc-99m and In-111 have been shown to have a high sensitivity for diagnosis and localization of protein-losing enteropathy; however, current evidence shows that low specificity may limit the usefulness of this imaging modality.

Though this technique has been reported to be useful in the diagnosis of protein-losing enteropathy, but no studies have compared the sensitivity of scintigraphy with fecal A1-AT determination. However, it may be extremely useful in identifying sites of involvement in protein-losing enteropathy (ie, stomach vs small intestine or even regional differences in the small bowel).

MRI

MRI has been used to identify lymphatic abnormalities yielding protein-losing enteropathy in both the intestine and mesentery, including dilated thoracic duct and mesenteric lymphatic as well as prominent subcutaneous lymphatics in the extremity.[27]

Previous
Next

Procedures

In addition to the investigations listed above to document and localize the protein-losing enteropathy, a thorough orderly evaluation is required in the patient with protein-losing enteropathy to determine the underlying etiology of the protein loss. This usually begins with cultures and other tests for the infectious causes listed above, serologic evaluation for the immune conditions listed above, and radiographic studies (nuclear medicine, contrast studies, CT scans, MRI) to localize the area of involvement and identify characteristic patterns.

Often, endoscopy is also performed to assess for specific mucosal features such as the hypertrophic gastric folds of Menetrier disease, the pseudomembranes of C difficile colitis, the scalloping of the duodenum in sprue, and the stigmata of inflammatory bowel disease. At the time of endoscopy, biopsies are obtained to confirm the histological findings listed below.

Previous
Next

Histologic Findings

See the list below:

  • Intestinal and more rarely gastric biopsies are at times required to definitively diagnose the underlying diseases that are the cause of the protein-losing enteropathy. Examples include Crohn disease, ulcerative colitis, celiac disease, graft versus host disease, Whipple disease, lymphoma, Hirschsprung disease, pseudomembranous colitis, eosinophilic gastroenteritis, allergic enteropathy, and some infectious diseases.
  • Lymphangiectasia, dilated lacteals in the mucosa, is also a histologic diagnosis.
Previous
 
 
Contributor Information and Disclosures
Author

Simon S Rabinowitz, MD, PhD, FAAP Professor of Clinical Pediatrics, Vice Chairman, Clinical Practice Development, Pediatric Gastroenterology, Hepatology, and Nutrition, State University of New York Downstate College of Medicine, The Children's Hospital at Downstate

Simon S Rabinowitz, MD, PhD, FAAP is a member of the following medical societies: American Gastroenterological Association, American Academy of Pediatrics, Phi Beta Kappa, American Association for the Advancement of Science, American College of Gastroenterology, American Medical Association, New York Academy of Sciences, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Jessica A Epstein State University of New York Downstate College of Medicine

Jessica A Epstein is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Psychiatric Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David A Piccoli, MD Chief of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia; Professor, University of Pennsylvania School of Medicine

David A Piccoli, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Royal College of Physicians and Surgeons of Canada

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching.

Additional Contributors

Robert Baldassano, MD Director, Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia; Professor, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Pennsylvania School of Medicine

Robert Baldassano, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Received consulting fee from Abbott, Inc for consulting.

Brianna Devito University at Buffalo, The State University of New York

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Barry K Wershil, MD, to the original writing and development of this article.

References
  1. Cakir M, Ersoz S, Akbulut UE. Disseminated cytomegalovirus infection and protein losing enteropathy as presenting feature of pediatric patient with Crohn's disease. Pediatr Gastroenterol Hepatol Nutr. 2015 Mar. 18 (1):60-5. [Medline].

  2. Magdo HS, Stillwell TL, Greenhawt MJ, Stringer KA, Yu S, Fifer CG, et al. Immune Abnormalities in Fontan Protein-Losing Enteropathy: A Case-Control Study. J Pediatr. 2015 Aug. 167 (2):331-7. [Medline].

  3. Schumacher KR, Stringer KA, Donohue JE, Yu S, Shaver A, Caruthers RL, et al. Fontan-associated protein-losing enteropathy and plastic bronchitis. J Pediatr. 2015 Apr. 166 (4):970-7. [Medline].

  4. Elkadri A, Thoeni C, Deharvengt SJ, Murchie R, Guo C, Stavropoulos JD, et al. Mutations in Plasmalemma Vesicle Associated Protein Result in Sieving Protein-Losing Enteropathy Characterized by Hypoproteinemia, Hypoalbuminemia, and Hypertriglyceridemia. Cell Mol Gastroenterol Hepatol. 2015 Jul. 1 (4):381-394.e7. [Medline].

  5. Damen G, de Klerk H, Huijmans J, den Hollander J, Sinaasappel M. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J Pediatr Gastroenterol Nutr. 2004 Mar. 38(3):282-7. [Medline].

  6. Bode L, Freeze HH. Applied glycoproteomics--approaches to study genetic-environmental collisions causing protein-losing enteropathy. Biochim Biophys Acta. 2006 Apr. 1760(4):547-59. [Medline].

  7. Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young. 2011 Aug. 21(4):363-77. [Medline].

  8. Ohuchi H, Yasuda K, Miyazaki A, Kitano M, Sakaguchi H, Yazaki S, et al. Haemodynamic characteristics before and after the onset of protein losing enteropathy in patients after the Fontan operation. Eur J Cardiothorac Surg. 2013 Mar. 43(3):e49-57. [Medline].

  9. Yu JJ, Yun TJ, Yun SC, Im YM, Lee SC, Shin HJ, et al. Low pulmonary vascular compliance predisposes post-Fontan patients to protein-losing enteropathy. Int J Cardiol. 2011 Sep 22. [Medline].

  10. Kim GB, Kwon BS, Bae EJ, Noh CI, Choi JY. Significance of circulating hepatocyte growth factor in protein-losing enteropathy after Fontan operation. Pediatr Cardiol. 2011 Oct. 32(7):917-23. [Medline].

  11. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg. 1998 May. 115(5):1063-73. [Medline].

  12. Mahjoub F, Sani MN, Tabari AK, Monajemzadeh M, Zandieh S. An unusual cause of protein losing enteropathy in a 2.5-year-old girl: meso-intestinal fibrosis. European J Pediatr Surg Rep. 2014 Jun. 2 (1):29-31. [Medline]. [Full Text].

  13. Weng MT, Wong JM, Shin SR, Yao M, Wei SC. Papillary thyroid cancer associated with light-chain amyloidosis initially presenting with small-bowel bleeding and protein-losing enteropathy. J Clin Oncol. 2010 Oct 10. 28(29):e557-9. [Medline].

  14. Hwang YY, Leung AY, Ng IO, Chan GS, Chan KW, Tse E, et al. Protein-losing enteropathy due to T-cell large granular lymphocyte leukemia. J Clin Oncol. 2009 Apr 20. 27(12):2097-8. [Medline].

  15. Burrow TA, Cohen MB, Bokulic R, et al. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy. J Pediatr. 2007 Feb. 150(2):202-6. [Medline].

  16. Damry N, Hottat N, Azzi N, Ferster A, Avni F. Unusual findings in two cases of Langerhans' cell histiocytosis. Pediatr Radiol. 2000 Mar. 30(3):196-9. [Medline].

  17. Alreheili K, AlMehaidib A, Alsaleem K, Banemi M, Aldekhail W, Al-Mayouf SM. Intestinal lymphangiectasia in a patient with infantile systemic hyalinosis syndrome: a rare cause of protein-losing enteropathy. Ann Saudi Med. 2012 Mar-Apr. 32(2):206-8. [Medline].

  18. Gökçe I, Gökçe S, Kiliç A, Bozlar U, Kocaoglu M, Ongürü O. Familial Mediteranean fever with protein-losing enteropathy due to constrictive pericarditis. World J Pediatr. 2011 Nov. 7(4):365-7. [Medline].

  19. Yamashita K, Saito M, Itoh M, et al. Juvenile polyposis complicated with protein losing gastropathy. Intern Med. 2009. 48(5):335-8. [Medline].

  20. Kok J, Chen SC, Anderson L, et al. Protein-losing enteropathy and hypogammaglobulinaemia as first manifestations of disseminated histoplasmosis coincident with Nocardia infection. J Med Microbiol. 2010 May. 59:610-3. [Medline].

  21. Ogawa E, Murata M, Unno M, et al. Protein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection. J Infect Chemother. 2009 Aug. 15(4):252-6. [Medline].

  22. Berni AD, Elias Júnior E, Arão Filho A, Paniago AM. Protein-losing enteropathy in paracoccidioidomycosis identified by scintigraphy: report of three cases. Braz J Infect Dis. 2010 Sep-Oct. 14(5):540-3. [Medline].

  23. Yamamoto M, Nishibuchi I, Matsuyama A, et al. Gastric carcinoma with protein-losing gastroenteropathy: report of a case. Surg Today. 2011 Jan. 41(1):125-9. [Medline].

  24. Salstrom JL, Kent M, Liang X, Wang M. Toddlers with anasarca and severe anemia: a lesson in preventive medicine. Curr Opin Pediatr. 2012 Feb. 24(1):129-33. [Medline].

  25. Hourigan SK, Anders RA, Mitchell SE, Schwarz KB, Lau H, Karnsakul W. Chronic diarrhea, ascites, and protein-losing enteropathy in an infant with hepatic venous outflow obstruction after liver transplantation. Pediatr Transplant. 2012 Nov. 16(7):E328-31. [Medline].

  26. Camarero Salces C, Enes Romero P, Redondo C, Rizo Pascual JM, Roy Ariño G. Collagenous colitis and collagenous gastritis in a 9 year old girl: a case report and review of the literature. Acta Gastroenterol Belg. 2011 Sep. 74(3):468-74. [Medline].

  27. Liu NF, Lu Q, Wang CG, Zhou JG. Magnetic resonance imaging as a new method to diagnose protein losing enteropathy. Lymphology. 2008 Sep. 41(3):111-5. [Medline].

  28. Kinsell L, Margen S, Tarver H. J Clin Invest. 1950. 29:238.

  29. Gordon RS. J Polym Sci. 1957. 31:191.

  30. Martinez-Sanchis B, Cortés-Vizcaíno V, Frontado-Morales L, Sopena-Novales P. Intestinal uptake of (99m)Tc-MDP: a case report of protein-losing enteropathy correlated with pathology findings from autopsy. Ann Nucl Med. 2011 Feb. 25(2):139-41. [Medline].

  31. Liu M, Liu L, Zhou HM. [Reversal of protein-losing enteropathy with heparin therapy in a patient after Fontan operation]. Zhonghua Er Ke Za Zhi. 2009 Jan. 47(1):76-7. [Medline].

  32. Schumacher KR, Cools M, Goldstein BH, Ioffe-Dahan V, King K, Gaffney D, et al. Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients. Pediatr Cardiol. 2011 Oct. 32(7):966-71. [Medline].

  33. Bac DJ, Van Hagen PM, Postema PT, et al. Octreotide for protein-losing enteropathy with intestinal lymphangiectasia. Lancet. 1995 Jun 24. 345(8965):1639. [Medline].

  34. Bai JC, Sambuelli A, Niveloni S, et al. Alpha 1-antitrypsin clearance as an aid in the management of patients with celiac disease. Am J Gastroenterol. 1991 Aug. 86(8):986-91. [Medline].

  35. Belamarich PF, Ortiz A, Mones RL. Severe hypoproteinemia and edema in association with varicella infection. Clin Pediatr (Phila). 1991 Jan. 30(1):56-8. [Medline].

  36. Boccon-Gibod LA, Krichen HA, Carlier-Mercier LM, et al. Digestive tract involvement with exudative enteropathy in Langerhans cell histiocytosis. Pediatr Pathol. 1992 Jul-Aug. 12(4):515-24. [Medline].

  37. Bode L, Murch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem. 2006 Mar 24. 281(12):7809-15. [Medline].

  38. Bryan RL, Newman J, Alexander-Williams J. Giant inflammatory polyposis in ulcerative colitis presenting with protein losing enteropathy. J Clin Pathol. 1990 Apr. 43(4):346-7. [Medline]. [Full Text].

  39. Chiu NT, Lee BF, Hwang SL, et al. Protein-losing enteropathy: diagnosis with 99mTc-labeled human serum albumin scintigraphy. Radiol. Apr 2001. 219(1):86-90.

  40. Cho CS, Min JK, Park SH, et al. Protein losing enteropathy associated with Henoch-Schonlein purpura in a patient with rheumatoid arthritis. Scand J Rheumatol. 1996. 25(5):334-6. [Medline].

  41. Cohen HA, Shapiro RP, Frydman M, Varsano I. Childhood protein-losing enteropathy associated with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr. 1991 Aug. 13(2):201-3. [Medline].

  42. Connor FL, Angelides S, Gibson M, et al. Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium-dextran scintigraphy. Pediatrics. 2003 Sep. 112(3 Pt 1):e242-7. [Medline]. [Full Text].

  43. Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case- control study. Clin Infect Dis. 1996 Jun. 22(6):932-7. [Medline].

  44. Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr. 1997 Mar. 130(3):474-8. [Medline].

  45. Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ. Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology. 1981 Oct. 81(4):777-80. [Medline].

  46. Ghilain JM, Martiat P, Fiasse R, et al. Exudative enteropathy caused by an acute graft-vs-host reaction. Apropos of a case report [in French]. Acta Gastroenterol Belg. 1990 Sep-Dec. 53(5-6):488-98. [Medline].

  47. Grill BB, Hillemeier AC, Gryboski JD. Fecal alpha 1-antitrypsin clearance in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1984. 3(1):56-61. [Medline].

  48. Groisman GM, George J, Berman D, Harpaz N. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol. 1994 Sep. 89(9):1548-51. [Medline].

  49. Hardikar W, Smith AL, Chow CW. Neonatal protein-losing enteropathy caused by intestinal lymphatic hypoplasia in siblings. J Pediatr Gastroenterol Nutr. 1997 Aug. 25(2):217-21. [Medline].

  50. Inoue Y, Ohtake T, Koga H, et al. Tc-99m albumin scintigraphy in protein-losing gastroenteropathy caused by gastric polyposis. Clin Nucl Med. 1998 May. 23(5):322-3. [Medline].

  51. Jacobs ML, Rychik J, Byrum CJ, Norwood WI Jr. Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg. 1996 Jan. 61(1):206-8. [Medline].

  52. Jain A, Reif S, O'Neil K, Gandhi A, Rossi T. Small intestinal bacterial overgrowth and protein-losing enteropathy in an infant with AIDS. J Pediatr Gastroenterol Nutr. 1992 Nov. 15(4):452-4. [Medline].

  53. Jarnum S, Westergaard H, Yssing M, Jensen H. Quantitation of gastrointestinal protein loss by means of FE59-labeled iron dextran. Gastroenterology. 1968 Aug. 55(2):229-41. [Medline].

  54. John AS, Driscoll DJ, Warnes CA, Phillips SD, Cetta F. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2011 Oct. 92(4):1451-6. [Medline].

  55. Kanter KR, Mahle WT, Vincent RN, Berg AM, Kogon BE, Kirshbom PM. Heart transplantation in children with a Fontan procedure. Ann Thorac Surg. 2011 Mar. 91(3):823-9; discussion 829-30. [Medline].

  56. Karbach U, Ewe K, Bodenstein H. Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut. 1983 Aug. 24(8):718-23. [Medline].

  57. Karbach U, Ewe K, Dehos H. Antiinflammatory treatment and intestinal alpha 1-antitrypsin clearance in active Crohn's disease. Dig Dis Sci. 1985 Mar. 30(3):229-35. [Medline].

  58. Keaney NP, Kelleher J. Faecal excretion of alpha 1-antitrypsin in protein-losing enteropathy. Lancet. 1980 Mar 29. 1(8170):711. [Medline].

  59. Kelly AM, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin Proc. 1998 Aug. 73(8):777-9. [Medline].

  60. Koga H, Iida M, Aoyagi K, et al. Generalized giant inflammatory polyposis in a patient with ulcerative colitis presenting with protein-losing enteropathy. Am J Gastroenterol. 1995 May. 90(5):829-31. [Medline].

  61. Konar A, Brown CB, Hancock BW, Moss S. Protein losing enteropathy as a sole manifestation of non-Hodgkin''s lymphoma. Postgrad Med J. 1986 May. 62(727):399-400. [Medline]. [Full Text].

  62. Korman SH, Bar-Oz B, Mandelberg A, Matoth I. Giardiasis with protein-losing enteropathy: diagnosis by fecal alpha 1- antitrypsin determination. J Pediatr Gastroenterol Nutr. 1990 Feb. 10(2):249-52. [Medline].

  63. Laine L, Politoske EJ, Gill P. Protein-losing enteropathy in acquired immunodeficiency syndrome due to intestinal Kaposi's sarcoma. Arch Intern Med. 1987 Jun. 147(6):1174-5. [Medline].

  64. Laster L, Waldmann TA, Fenster LF, Singleton JW. Albumin metabolism in patients with Whipple''s disease. J Clin Invest. 1966 May. 45(5):637-44. [Medline]. [Full Text].

  65. Madina EH, Soliman AT, Morsi MR. Protein losing enteropathy in the different forms of protein-energy malnutrition. J Trop Pediatr. 1987 Oct. 33(5):254-6. [Medline].

  66. Matoth I, Granot E, Gorenstein A, et al. Gastrointestinal protein loss in children recovering from burns. J Pediatr Surg. 1991 Oct. 26(10):1175-8. [Medline].

  67. Mertens L, Hagler DJ, Sauer U, et al. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg. 1998 May. 115(5):1063-73. [Medline].

  68. Meuwissen SG, Ridwan BU, Hasper HJ, Innemee G. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Menetrier Study Group. Scand J Gastroenterol Suppl. 1992. 194:1-7. [Medline].

  69. Molina JF, Brown RF, Gedalia A, Espinoza LR. Protein losing enteropathy as the initial manifestation of childhood systemic lupus erythematosus. J Rheumatol. 1996 Jul. 23(7):1269-71. [Medline].

  70. Nakano S, Kuramochi S, Hosoda Y, Miura S. Protein-losing enteropathy due to intestinal lymphangiectasia accompanied by mesenteric lymph node fibrosis. Pathol Int. 1996 Nov. 46(11):883-6. [Medline].

  71. Nakase H, Itani T, Mimura J, et al. Transient protein-losing enteropathy associated with cytomegalovirus infection in a noncompromised host: a case report. Am J Gastroenterol. 1998 Jun. 93(6):1005-6. [Medline].

  72. Petersen VP, Hastrup J. Protein losing enteropathy in constrictive pericarditis. Acta Med Scand. 1963. 173:401.

  73. Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet. 1989 Jun 17. 1(8651):1353-5. [Medline].

  74. Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol. 1991 Sep 15. 68(8):819-21. [Medline].

  75. Sierra C, Calleja F, Picazo B, Martinez-Valverde A. Protein-losing enteropathy secondary to Fontan procedure resolved after cardiac transplantation. J Pediatr Gastroenterol Nutr. 1997 Feb. 24(2):229-30. [Medline].

  76. Strober W, Wochner RD, Carbone PP, Waldmann TA. Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. The Journal of Clinical Investigation. 1967 Oct. 46(10):1643-56. [Medline].

  77. Su J, Smith MB, Rerknimitr R, Morrow D. Small intestine bacterial overgrowth presenting as protein-losing enteropathy. Dig Dis Sci. 1998 Mar. 43(3):679-81. [Medline].

  78. Sunagawa T, Kinjo F, Gakiya I, et al. Successful long-term treatment with cyclosporin A in protein losing gastroenteropathy. Intern Med. 2004 May. 43(5):397-9. [Medline].

  79. Sunheimer RL, Finck C, Mortazavi S, et al. Primary lupus-associated protein-losing enteropathy. Ann Clin Lab Sci. 1994 May-Jun. 24(3):239-42. [Medline].

  80. Sutton DL, Kamath KR. Giardiasis with protein-losing enteropathy. J Pediatr Gastroenterol Nutr. 1985 Feb. 4(1):56-9. [Medline].

  81. Therrien J, Webb GD, Gatzoulis MA. Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation?. Heart. 1999 Aug. 82(2):241-3. [Medline]. [Full Text].

  82. Tift WL, Lloyd JK. Intestinal lymphangiectasia. Long-term results with MCT diet. Arch Dis Child. 1975 Apr. 50(4):269-76. [Medline].

  83. Tsutsumi A, Sugiyama T, Matsumura R, et al. Protein losing enteropathy associated with collagen diseases. Ann Rheum Dis. 1991 Mar. 50(3):178-81. [Medline].

  84. Tusseau F, Beaugerie L, Cardon B, Rozenbaum W, Gendre JP, Le Quintrec Y. [Anasarca caused by exudative enteropathy due to digestive Kaposi's sarcoma]. Presse Med. 1989 Sep 16. 18(28):1393. [Medline].

  85. Waldmann TA. Gastrointestinal protein loss demonstrated by 51Cr-labelled albumin. Lancet. 1961. July:121-3.

  86. Wargny D, Dichy J, de Broucker F, et al. Protein-losing enteropathy caused by intestinal metastases of melanosarcoma [in French]. J Radiol. 1989 Oct. 70(10):577-9. [Medline].

  87. Westphal V, Murch S, Kim S, et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am J Pathol. 2000 Dec. 157(6):1917-25. [Medline]. [Full Text].

  88. Wing-Harkins DL, Dellinger GW, Lynch C, Mihas AA. Eosinophilic gastro-enteritis associated with protein-losing enteropathy and protein C deficiency. J Int Med Res. 1996 Jan-Feb. 24(1):155-63. [Medline].

  89. Yamada M, Sumazaki R, Adachi H, et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr. 1997 Mar. 156(3):182-5. [Medline].

  90. Zellers TM, Brown K. Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol. 1996 Mar-Apr. 17(2):115-7. [Medline].

  91. Gursu HA, Varan B, Erdogan I. Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy. Cardiol Young. 2014 Aug. 24 (4):764-6. [Medline].

  92. Mizuochi T, Suda K, Seki Y, Yanagi T, Yoshimoto H, Kudo Y, et al. Successful diuretics treatment of protein-losing enteropathy in Noonan syndrome. Pediatr Int. 2015 Apr. 57 (2):e39-41. [Medline].

  93. Schumacher KR, Gossett J, Guleserian K, Naftel DC, Pruitt E, Dodd D, et al. Fontan-associated protein-losing enteropathy and heart transplant: A Pediatric Heart Transplant Study analysis. J Heart Lung Transplant. 2015 Sep. 34 (9):1169-76. [Medline].

  94. Khalesi M, Nakhaei AA, Seyed AJ, Treglia G, Zakavi SR, Sadeghi R, et al. Diagnostic accuracy of nuclear medicine imaging in protein losing enteropathy : systematic review and meta-analysis of the literature. Acta Gastroenterol Belg. 2013 Dec. 76 (4):413-22. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.